These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Glutathione-triggered dual release of doxorubicin and camptothecin for highly efficient synergistic anticancer therapy.
    Author: Li Y, Yang H, Yao J, Yu H, Chen X, Zhang P, Xiao C.
    Journal: Colloids Surf B Biointerfaces; 2018 Sep 01; 169():273-279. PubMed ID: 29787951.
    Abstract:
    An amphiphilic biodegradable prodrug (PLG-g-mPEG/CPT) was synthesized by conjugating disulfide-containing camptothecin (CPT) to poly(L-glutamic acid)-graft-methoxy poly(ethylene glycol) (PLG-g-mPEG) through esterification reaction. The amphiphilic prodrugs could self-assemble into micellar nanoparticles and encapsulate doxorubicin (DOX) in aqueous solution at pH 7.4. The treatment of the nanoparticles with reducing glutathione (GSH) at cytosolic concentration (10 mM) significantly promoted the in vitro dual release of DOX and CPT from the micelles. The results of flow cytometry (FCM) and confocal laser scanning microscopy (CLSM) manifested that the intracellular release of DOX and CPT from the micelles was enhanced by increasing the intracellular GSH level. Consistently, the MCF-7 cell killing mediated by the micelles was also intracellular GSH concentration-dependent. The low combination index (CI) value of < 0.3 demonstrated the high synergistic effect of DOX and CPT co-delivered by the nanoparticles in tumor cell killing. Therefore, this GSH-triggered dual release drug delivery system is a promising strategy for combination cancer therapy.
    [Abstract] [Full Text] [Related] [New Search]